MMMassimo Milli

Massimo Milli

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Massimo Milli has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ANMCO position paper E-health integration in cardiology clinical care framework

    by Fabiana Lucà, Gian Franco Gensini, Francesco Gabbrielli, Daniela Aschieri, Michela Barisone, Ilaria Battistoni, Francesco Antonio Benedetto, Claudio Bilato, Giovanni Bisignani, Roberto Ceravolo, et al.

    The ongoing digital transformation is reshaping organisational and care delivery models in cardiology, positioning telemedicine as a pivotal tool to address increasing clinical and demographic complexity. This manuscript presents a comprehensive and critical overview of telemedicine applications in cardiovascular care, with a focus on its role in strengthening hospital-community integration, its deployment within hospital-based healthcare systems, and the associated regulatory and operational frameworks. The analysis encompasses the management of chronic cardiovascular conditions, such as heart failure and atrial fibrillation, through telemonitoring, telecontrol, televisit, and teleconsultation. Additionally, it explores the use of digital technologies in post-myocardial infarction follow-up, oral anticoagulation management, preoperative assessment, and care for elderly patients. The review also highlights the challenges and opportunities linked to digital infrastructure, interoperability, data protection, and healthcare professional training.


  • Open Access

    ANMCO position paper: ANMCO general assembly 2024—the role of the cardiologist in the management of cardiovascular chronicity

    by Simona Giubilato, Pietro Scicchitano, Claudio Bilato, Marco Corda, Leonardo De Luca, Massimo Di Marco, Giovanna Geraci, Attilio Iacovoni, Massimo Milli, Alessandro Navazio, et al.

    Cardiovascular diseases remain the leading cause of mortality globally and in Italy, with a growing burden exacerbated by ageing populations and underdeveloped strategies for managing chronic cardiovascular conditions. This position paper, resulting from the 2024 ANMCO General Assembly, addresses the current state of cardiovascular chronicity management in Italy, highlighting critical gaps and proposing sustainable, integrative solutions. Despite improvements in acute cardiovascular care, the lack of structured post-acute management, insufficient adoption of secondary prevention protocols, limited access to innovative therapies, and a slow digital transition continue to hinder effective chronic care. The document stresses the pivotal role of cardiologists, not only in acute intervention but also in long-term care and secondary prevention, emphasising the need for a multidisciplinary, multichannel healthcare model. The paper explores the potential of e-Health and artificial intelligence to revolutionize chronic disease management. It advocates for the widespread implementation of integrated care pathways, digital tools like electronic health records and telemedicine platforms, which together could enhance early detection, patient monitoring, and therapeutic adherence while reducing unnecessary hospitalisations. It also underscores the necessity of updating national and regional pharmaceutical policies to improve equitable access to disease-modifying therapies. Furthermore, the integration of palliative care in end-stage cardiovascular disease and the enhancement of post-acute care networks are deemed essential. Ultimately, the document advocates for a comprehensive systemic and cultural transformation spearheaded by scientific societies such as ANMCO, where technological innovation, organisational reform, and patient-centred care align to ensure a sustainable and universally accessible healthcare system. This vision is consistent with the objectives of the PNRR, the 2030 Agenda, and, most importantly, the foundational principles of the Italian Constitution.

  • Open Access

    Position paper ANMCO in collaboration with Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P): ‘the management of hospital discharge’

    by Carmine Riccio, Francesco Fattirolli, Marco Ambrosetti, Giovanna Geraci, Massimo Milli, Maurizio Giuseppe Abrignani, Maria Elisabetta Angelino, Michela Barisone, Barbara Biffi, Arturo Cesaro, et al.

    Hospital discharge is a pivotal stage in the continuum of care, marking the transition from the acute clinical episode to subsequent therapeutic management. Rather than being a purely administrative procedure, discharge is a multifaceted process that requires structured planning, clear communication, and the coordinated participation of all healthcare stakeholders, with the patient playing a central role. Inadequate discharge processes may adversely affect clinical outcomes and increase hospital readmission rates, resulting in sub-optimal utilization of healthcare resources. This issue is particularly relevant in the context of an ageing and increasingly frail population, characterized by a high burden of comorbidities and complex clinical needs. In this setting, discharge planning should be treated as an integral component of the care pathway, embedded within a comprehensive, coordinated model of care. This document proposes an updated, practical framework for hospital discharge management, grounded in current scientific evidence and multidisciplinary expertise. Its primary objective is to enhance continuity of care, support individualized treatment strategies, and ultimately improve patient outcomes. Specifically, this paper aims to provide clinical cardiologists with a structured reference tool for discharge management, including actionable recommendations to strengthen physician–patient communication, optimize therapeutic regimens, and promote better health outcomes.

  • Open Access

    Occupational Hazards in Cardiac Catheterization Laboratories: Radiation and Beyond-ANMCO Position Paper Update 2026

    by Fabiana Lucà, Eugenio Picano, Daniela Aschieri, Ilaria Battistoni, Claudio Bilato, Stefania Angela Di Fusco, Giovanna Geraci, Vered Gil Ad, Attilio Iacovoni, Barbara Maria Teresa Mabritto, et al.

    Interventional cardiology has profoundly transformed the management of cardiovascular disease; however, working within the cardiac catheterization laboratory exposes healthcare professionals to substantial occupational hazards. Four principal risks can be identified: (i) malignancy and non-malignant sequelae related to chronic exposure to ionizing radiation; (ii) musculoskeletal injury associated with prolonged use of heavy radioprotective equipment; (iii) exposure to blood-borne pathogens and other infectious agents; and (iv) work-related psychological strain. Among these, cumulative radiation exposure remains the most consequential and historically under-recognized threat. Although the radiation dose which operators receive during a single procedure is markedly lower than that delivered to patients, healthcare professionals are subjected to repeated, lifelong exposure. For a high-volume interventional cardiologist, the annual effective dose may substantially exceed that of other radiation-exposed professionals, including nuclear industry workers and diagnostic radiologists. Importantly, unlike radiologists, many cardiologists receive limited formal training in radiation physics and radiobiology, which may lead to limited awareness of dose-optimization strategies and stochastic risk. Contemporary epidemiological evidence has refined our understanding of the biological effects of chronic low-dose and low-dose-rate radiation. Risk estimates for malignancy have progressively increased as follow-up durations have lengthened and methodological approaches have improved. Moreover, emerging data suggest that sustained low-dose exposure may confer an elevated risk of cardiovascular disease, thereby extending concern beyond oncological endpoints. Occupational exposure varies greatly depending on the location: doses to the head can be several times higher than doses to the chest, with a predominance on the left side attributable to the position of the operator in relation to the X-ray source. In addition to the well-established association with posterior subcapsular cataracts, observational studies have reported potential links between long-term occupational exposure and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases, although causality remains to be definitively established. Mitigation of these risks necessitates a paradigm shift towards a rigorous culture of radiation safety. Institutional commitment is essential, encompassing advanced shielding systems, ceiling-suspended protection, real-time dosimetry with immediate feedback, and systematic optimization of imaging protocols. Ultimately, the future of the field may depend on the progressive adoption of radiation-sparing and radiation-free technologies, including intracardiac and intracoronary ultrasound, electro anatomical mapping systems, and non-fluoroscopic navigation platforms. In parallel, robot-assisted procedures enable remote manipulation of the catheter promise to reduce the operator's direct exposure. The pursuit of a zero-radiation environment in the workplace should not be considered an ambitious ideal but a strategic priority to safeguard the next generation of interventional cardiologists.


  • Open Access

    ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum

    by Leonardo De Luca, Claudio Bilato, Alessandro Navazio, Marco Corda, Massimo Milli, Pietro Scicchitano, Massimo Di Marco, Carmine Riccio, Giovanna Geraci, Attilio Iacovoni, et al.

    Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a pivotal therapeutic agent in the management of the cardio-renal-metabolic continuum. Initially developed for glycaemic control in Type 2 diabetes mellitus, its benefits extend far beyond glucose regulation. Clinical trials have demonstrated semaglutide’s potential to reduce major adverse cardiovascular events, particularly in overweight/obese patients with high cardiovascular risk, as well as improving functional capacity in patients suffering from heart failure with preserved left ventricular function. Additionally, it has shown promise in improving renal outcomes, such as slowing the progression of albuminuria and reducing the risk of chronic kidney disease in diabetic populations. These effects are likely due to its multifaceted mechanisms, including anti-inflammatory properties, weight reduction, blood pressure lowering, and direct renal protection. This review synthesizes current evidence on semaglutide’s role in the interrelated domains of cardiovascular, renal, and metabolic health.


  • Open Access

    ANMCO position paper ‘Hypertrophic cardiomyopathy: from diagnosis to treatment’

    by Cristina Chimenti, Attilio Iacovoni, Andrea Montalto, Michele Emdin, Iacopo Olivotto, Cristina Basso, Benedetta Carla De Chiara, Irene Bottillo, Claudio Mario Ciampi, Santo Dellegrottaglie, et al.

    Hypertrophic cardiomyopathy (HCM) is a non-rare genetic cardiomyopathy, with an estimated prevalence of 1:500, characterized by an increase in the left ventricular wall thickness in the absence of increased loading conditions. The hypertrophy is mostly asymmetric and predominantly affects the basal septum and anterior wall. Left ventricular outflow tract obstruction, at rest or after provocative tests, is detected in many patients and represents the primary cause of reduced functional capacity, as well as an independent predictor of sudden cardiac death and advanced heart failure. Until ∼1 year ago, symptomatic patients despite maximal therapy with β-blockers or calcium channel blockers plus disopyramide had only basal septal reduction therapy through myectomy or septal alcoholization as additional therapeutic options. Today, a new class of drugs that inhibit cardiac myosin activity is available for patients with obstructive HCM. In light of the new treatment perspectives, the correct clinical-therapeutic classification of affected patients becomes of fundamental importance for the cardiologist. The aim of this position paper is to increase the knowledge of cardiologists in the field of HCM, defining its epidemiological, genetic, and pathological characteristics, identifying the diagnostic criteria and instrumental methods capable of stratifying the risk profile, with the aim of an optimal therapy tailored on the single patient.


  • Open Access

    ANMCO position paper: functional reorganization of Intensive Cardiac Care Units (ICCUs) in Italy

    by Serafina Valente, Paolo Trambaiolo, Gianni Casella, Alice Sacco, Carlotta Sorini Dini, Andrea Farina, Leonardo De Luca, Giovanna Geraci, Emanuele Tizzani, Maddalena Lettino, et al.

    Recently, intensive cardiac care units (ICCUs) have undergone a significant transformation related to the evolution in management of acute coronary syndrome and influenced by other factors such as the epidemiological transition, the increasing complexity of clinical cases, the technological advancement, and the growth of clinical and scientific expertise of cardiologists. In the context of this evolution, a functional reorganization of ICCUs in Italy has to be implemented in order to meet the changing needs of the population with cardiovascular disease requiring critical care. Therefore, the Italian Association of Hospital Cardiologists (ANMCO) proposes this position paper for the reorganization of CICUs into three levels with increasing functional complexity, based on the hospital characteristics, the available technology, and the clinical cases treated. The system would be functionally integrated into a regional ICCU organization modelled on a time-dependent care network. This proposed network aims to standardize diagnostic and therapeutic protocols and establish unified data collection registries to facilitate self-assessment and support clinical research. The document delineates specific requirements for each ICCU level, including the management of clinical cases, the expertise of intensive care cardiologists, the technological facilities, and the medical and nursing staff needed to ensure optimal care delivery.